johnston th - Search Results

Year	Number of Results
1982	1
2004	1
2005	3
2006	4
2008	5
2009	2
2010	9
2011	7
2012	9
2013	6
2014	1
2015	4
2016	1
2017	1
2018	4
2019	3
2020	3
2021	1
2022	1

1

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM. Johnston TH, et al. Neuropharmacology. 2019 Mar 15;147:11-27. doi: 10.1016/j.neuropharm.2018.05.035. Epub 2018 Jun 1. Neuropharmacology. 2019. PMID: 29907424 Review.

2

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. Huot P, et al. Among authors: johnston th. Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Pharmacol Rev. 2013. PMID: 23319549 Review.

3

NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.

Barth AL, Schneider JS, Johnston TH, Hill MP, Brotchie JM, Moskal JR, Cearley CN. Barth AL, et al. Among authors: johnston th. Mov Disord. 2020 Apr;35(4):640-649. doi: 10.1002/mds.27962. Epub 2020 Jan 22. Mov Disord. 2020. PMID: 31967361

4

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT. Brigham EF, et al. Among authors: johnston th. J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7. J Pharmacol Exp Ther. 2018. PMID: 30087157

5

A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.

Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. Fox SH, et al. Among authors: johnston th. Mov Disord. 2012 Sep 15;27(11):1373-8. doi: 10.1002/mds.25133. Epub 2012 Sep 13. Mov Disord. 2012. PMID: 22976821 Review.

6

Advances in the delivery of treatments for Parkinson's disease.

Johnston TH, Fox SH, Brotchie JM. Johnston TH, et al. Expert Opin Drug Deliv. 2005 Nov;2(6):1059-73. doi: 10.1517/17425247.2.6.1059. Expert Opin Drug Deliv. 2005. PMID: 16296809 Review.

7

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Johnston TH, et al. Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21. Mov Disord. 2019. PMID: 30575996

8

The selective 5-HT_1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.

Depoortere R, Johnston TH, Fox SH, Brotchie JM, Newman-Tancredi A. Depoortere R, et al. Among authors: johnston th. Parkinsonism Relat Disord. 2020 Sep;78:151-157. doi: 10.1016/j.parkreldis.2020.08.009. Epub 2020 Aug 13. Parkinsonism Relat Disord. 2020. PMID: 32846366

9

A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.

Schneider JS, Marshall CA, Keibel L, Snyder NW, Hill MP, Brotchie JM, Johnston TH, Waterhouse BD, Kortagere S. Schneider JS, et al. Among authors: johnston th. Exp Neurol. 2021 Jan;335:113514. doi: 10.1016/j.expneurol.2020.113514. Epub 2020 Oct 22. Exp Neurol. 2021. PMID: 33141071 Free PMC article.

10

Drugs in development for Parkinson's disease.

Johnston TH, Brotchie JM. Johnston TH, et al. Curr Opin Investig Drugs. 2004 Jul;5(7):720-6. Curr Opin Investig Drugs. 2004. PMID: 15298067 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results